Intensive hemodialysis and hemoperfusion treatment of Amanita mushroom poisoning.
Over a period of fifteen years, 41 patients including 23 males and 18 females with Amanita mushroom poisoning were treated at the University Hospital of Lund, Sweden. The intensity of poisoning was graded according to serum transaminase elevations and prothrombin time reductions. Severity was mild in 16 patients (Group A), moderate in 14 (Group B) and severe in 11 (Group C). Members of Group C reported shorter latency periods before the onset of symptoms, (10 +/- 1 hours, P < 0.05) and longer delays in treatment, (34 +/- 4 hours), than did the other patients. Intensive treatment was begun before the results of urine amatoxin assay were reported. Treatment consisted of: fluid and electrolyte replacement, oral activated charcoal and lactulose, i.v. penicillin, combined hemodialysis and hemoperfusion in two 8 hour sessions, some received i.v. thioctic acid, other i.v. silibinin, all received a special diet. This combination of treatment modalities was used to accelerate the elimination of amatoxin from the patients' bodies. The longest period of hospitalization, 13 +/- 2 days, was required by the patients of Group C (p < 0.01). All patients improved and were discharged from the hospital asymptomatic. No sequelae were later reported for the majority of those moderately and severely poisoned. We have concluded that intensive combined treatment applied in these cases is effective in relieving patients with both moderate and severe amanitin poisoning.
Sabeel
A I
AI
Department of Nephrology, University Hospital, Lund, Sweden.
Kurkus
J
J
Lindholm
T
T
D000328:Adult; D000545:Amanita; D000935:Antifungal Agents / Q000627:therapeutic use; D002606:Charcoal / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D004032:Diet; D005260:Female; D006464:Hemoperfusion; D006801:Humans; D007792:Lactulose / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009145:Mushroom Poisoning / Q000145:classification / Q000628:therapy*; D010406:Penicillins / Q000627:therapeutic use; D006435:Renal Dialysis; D012720:Severity of Illness Index; D012838:Silymarin / Q000627:therapeutic use; D008063:Thioctic Acid / Q000627:therapeutic use
D000935:Antifungal Agents; D010406:Penicillins; D012838:Silymarin; D002606:Charcoal; D007792:Lactulose; D008063:Thioctic Acid